StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a report released on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Several other brokerages also recently weighed in on ALIM. HC Wainwright downgraded Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a research note on Tuesday, June 25th. Maxim Group reiterated a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.
View Our Latest Report on Alimera Sciences
Alimera Sciences Price Performance
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The company had revenue of $27.00 million for the quarter, compared to analysts’ expectations of $25.76 million. Equities analysts forecast that Alimera Sciences will post -0.13 earnings per share for the current year.
Hedge Funds Weigh In On Alimera Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of ALIM. Vanguard Group Inc. lifted its holdings in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares during the last quarter. Glazer Capital LLC bought a new stake in Alimera Sciences in the second quarter valued at $3,067,000. Ancora Advisors LLC acquired a new position in shares of Alimera Sciences during the first quarter valued at $915,000. Renaissance Technologies LLC grew its position in shares of Alimera Sciences by 3.9% during the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after acquiring an additional 6,900 shares during the last quarter. Finally, Deltec Asset Management LLC bought a new position in shares of Alimera Sciences during the second quarter worth about $690,000. 99.83% of the stock is currently owned by institutional investors and hedge funds.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Read More
- Five stocks we like better than Alimera Sciences
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What does consumer price index measure?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- With Risk Tolerance, One Size Does Not Fit All
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.